IPHA Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -- compared to Innate Pharma SA's net margin of --. Innate Pharma SA's return on equity of -72.79% beat DBV Technologies SA's return on equity of -280.59%.

Innate Pharma SA has a consensus price target of $5.15, signalling upside risk potential of 171.26%. On the other hand DBV Technologies SA has an analysts' consensus of $20.57 which suggests that it could grow by 58.35%. Given that Innate Pharma SA has higher upside potential than DBV Technologies SA, analysts believe Innate Pharma SA is more attractive than DBV Technologies SA.

Innate Pharma SA has a beta of -0.081, which suggesting that the stock is 108.148% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.102, suggesting its less volatile than the S&P 500 by 210.179%.

Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Innate Pharma SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Innate Pharma SA's net income of -- is lower than DBV Technologies SA's net income of -$33M. Notably, Innate Pharma SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 24.54x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Inventiva SA has a net margin of -- compared to Innate Pharma SA's net margin of --. Innate Pharma SA's return on equity of -72.79% beat Inventiva SA's return on equity of --.

Innate Pharma SA has a consensus price target of $5.15, signalling upside risk potential of 171.26%. On the other hand Inventiva SA has an analysts' consensus of $15.33 which suggests that it could grow by 270.37%. Given that Inventiva SA has higher upside potential than Innate Pharma SA, analysts believe Inventiva SA is more attractive than Innate Pharma SA.

Innate Pharma SA has a beta of -0.081, which suggesting that the stock is 108.148% less volatile than S&P 500. In comparison Inventiva SA has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.433%.

Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend.

Innate Pharma SA quarterly revenues are --, which are smaller than Inventiva SA quarterly revenues of --. Innate Pharma SA's net income of -- is lower than Inventiva SA's net income of --. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 24.54x versus 24.10x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.

Nanobiotix SA has a net margin of -- compared to Innate Pharma SA's net margin of --. Innate Pharma SA's return on equity of -72.79% beat Nanobiotix SA's return on equity of --.

Innate Pharma SA has a consensus price target of $5.15, signalling upside risk potential of 171.26%. On the other hand Nanobiotix SA has an analysts' consensus of $14.74 which suggests that it could fall by -29.78%. Given that Innate Pharma SA has higher upside potential than Nanobiotix SA, analysts believe Innate Pharma SA is more attractive than Nanobiotix SA.

Innate Pharma SA has a beta of -0.081, which suggesting that the stock is 108.148% less volatile than S&P 500. In comparison Nanobiotix SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanobiotix SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. Nanobiotix SA pays out -- of its earnings as a dividend.

Innate Pharma SA quarterly revenues are --, which are smaller than Nanobiotix SA quarterly revenues of --. Innate Pharma SA's net income of -- is lower than Nanobiotix SA's net income of --. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Nanobiotix SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 24.54x versus 29.34x for Nanobiotix SA. Usually stocks with elevated PS ratios are considered overvalued.

Sanofi has a net margin of -- compared to Innate Pharma SA's net margin of 36.7%. Innate Pharma SA's return on equity of -72.79% beat Sanofi's return on equity of 12.45%.

Innate Pharma SA has a consensus price target of $5.15, signalling upside risk potential of 171.26%. On the other hand Sanofi has an analysts' consensus of $60.13 which suggests that it could grow by 21.01%. Given that Innate Pharma SA has higher upside potential than Sanofi, analysts believe Innate Pharma SA is more attractive than Sanofi.

Innate Pharma SA has a beta of -0.081, which suggesting that the stock is 108.148% less volatile than S&P 500. In comparison Sanofi has a beta of 0.446, suggesting its less volatile than the S&P 500 by 55.394%.

Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanofi offers a yield of 4.42% to investors and pays a quarterly dividend of $2.20 per share. Innate Pharma SA pays -- of its earnings as a dividend. Sanofi pays out 66.53% of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Innate Pharma SA quarterly revenues are --, which are smaller than Sanofi quarterly revenues of $12.2B. Innate Pharma SA's net income of -- is lower than Sanofi's net income of $4.5B. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Sanofi's PE ratio is 12.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 24.54x versus 2.86x for Sanofi. Usually stocks with elevated PS ratios are considered overvalued.